drugset / Trial / NCT04640181
Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT)
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a multicenter, randomized trial to study the potential benefit of treatments with a direct FXa inhibitor (rivaroxaban) versus standard of care dose subcutaneous low molecular weight heparin (LMWH) (Lovenox) in hospitalized subjects with COVID-19.
Timeline
- Start
- 2020-12-01
- Primary completion
- 2021-06-28
- Completion
- 2021-06-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Enoxaparin sodium | Other / unclassified | 1 mg/kg | Subcutaneous |
| Comparator | Enoxaparin sodium | Other / unclassified | 40 mg | Subcutaneous |
| Comparator | Rivaroxaban | Other / unclassified | 10 mg | Oral |
| Comparator | Rivaroxaban | Other / unclassified | 20 mg | Oral |